SynAgile is developing DopaFuse® , the first patient-friendly, non-invasive therapy for continuous delivery of levodopa and carbidopa.SynAgile was founded by highly successful serial inventor-entrepreneurs Adam Heller (CSO) and Ephraim Heller (CEO). The father-son team have over 300 patents (most in use) and a track record which includes the founding of AngioScore (sold for $235 million) and TheraSense (which went public and ...
SynAgile is developing DopaFuse® , the first patient-friendly, non-invasive therapy for continuous delivery of levodopa and carbidopa.SynAgile was founded by highly successful serial inventor-entrepreneurs Adam Heller (CSO) and Ephraim Heller (CEO). The father-son team have over 300 patents (most in use) and a track record which includes the founding of AngioScore (sold for $235 million) and TheraSense (which went public and was later sold for $1.2 billion). Adam Heller is also a coinventor of the first commercialized lithium thionyl chloride battery and a recipient
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.